纳武利尤单抗联合伊匹木单抗一线治疗晚期非小细胞肺癌(CheckMate 012):开放标签、1期、多队列研究结果
CheckMate 012研究在美国8个学术中心入组78例初治晚期非小细胞肺癌患者,随机接受纳武利尤单抗联合伊匹木单抗两种给药方案。主要终点安全性可耐受,确认客观缓解率分别为47%和38%,PD-L1≥1%患者均为57%,作者认为支持进一步3期评估。
要点
- 纳武利尤单抗联合伊匹木单抗一线治疗晚期非小细胞肺癌安全性可耐受,无治疗相关死亡。
- 伊匹木单抗每12周组确认客观缓解率47%,每6周组38%。
- PD-L1≥1%患者中两组确认客观缓解率均为57%。
核心结论
- 在非小细胞肺癌中,一线纳武利尤单抗联合伊匹木单抗安全性可耐受,并显示出以高缓解率和持久缓解为特征的令人鼓舞的临床活性。
- 据作者所知,本研究结果首次提示该联合方案较抗PD-1单药治疗可能带来更优获益,支持在3期研究中进一步评估该联合方案。
研究设计与样本
- 开放标签、1期、多队列研究(CheckMate 012),本报告队列在美国8个学术中心入组。
- 入组标准为年龄18岁及以上、组织学或细胞学确认的复发IIIb期或IV期、未接受化疗的非小细胞肺癌患者。
- 患者按1:1:1随机分配至纳武利尤单抗1 mg/kg每2周联合伊匹木单抗1 mg/kg每6周组、纳武利尤单抗3 mg/kg每2周联合伊匹木单抗1 mg/kg每12周组、或纳武利尤单抗3 mg/kg每2周联合伊匹木单抗1 mg/kg每6周组,直至疾病进展、不可接受毒性或撤回知情同意。
- 本报告呈现后两个队列的数据,这两个队列被认为可能适合进一步临床开发;另一队列及若干早期队列数据见附录。
- 主要终点为安全性和耐受性,在所有接受治疗的患者中评估;研究注册号NCT01454102,正在进行中。
主要发现
- 2014年5月15日至2015年3月25日,78例患者随机分配至伊匹木单抗每12周组(n=38)或每6周组(n=40);每6周组1例在治疗前被排除,实际接受治疗77例(每12周组38例,每6周组39例)。
- 截至2016年1月7日数据截止,每12周组29例(76%)、每6周组32例(82%)患者已终止治疗。
- 3-4级治疗相关不良事件在每12周组14例(37%)、每6周组13例(33%);最常见为脂肪酶升高(每12周组3例[8%] vs 每6周组0例)、肺炎(2例[5%] vs 1例[3%])、肾上腺功能不全(1例[3%] vs 2例[5%])和结肠炎(1例[3%] vs 2例[5%])。
- 治疗相关严重不良事件在每12周组12例(32%)、每6周组11例(28%);任何级别治疗相关不良事件导致停药在每12周组4例(11%)、每6周组5例(13%);无治疗相关死亡。
- 确认客观缓解在每12周组18例(47%[95%CI 31-64])、每6周组15例(38%[95%CI 23-55]);两组中位缓解持续时间均未达到,中位随访时间每12周组12.8个月(IQR 9.3-15.5)、每6周组11.8个月(IQR 6.7-15.9)。
关键数值与推荐
- 3-4级治疗相关不良事件:伊匹木单抗每12周组14/38例(37%)vs 每6周组13/39例(33%)。
- 治疗相关严重不良事件:每12周组12/38例(32%)vs 每6周组11/39例(28%)。
- 确认客观缓解率:每12周组47%(95%CI 31-64)vs 每6周组38%(95%CI 23-55)。
- PD-L1≥1%患者确认客观缓解率:每12周组57%(12/21)vs 每6周组57%(13/23)。
临床怎么用
- 作者认为,一线纳武利尤单抗联合伊匹木单抗在非小细胞肺癌中安全性可耐受且显示令人鼓舞的临床活性,支持在3期研究中进一步评估该联合方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for NSCLC. METHODS: The open-label, phase 1, multicohort study (CheckMate 012) cohorts reported here were enrolled at eight US academic centres. Eligible patients were aged 18 years or older with histologically or cytologically confirmed recurrent stage IIIb or stage IV, chemotherapy-naive NSCLC. Patients were randomly assigned (1:1:1) by an interactive voice response system to receive nivolumab 1 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks, nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 12 weeks, or nivolumab 3 mg/kg every 2 weeks plus ipilimumab 1 mg/kg every 6 weeks until disease progression, unacceptable toxicities, or withdrawal of consent. Data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented in this report; data from the other cohort (as well as several earlier cohorts) are described in the appendix. The primary outcome was safety and tolerability, assessed in all treated patients. This ongoing study is registered with ClinicalTrials.gov, number NCT01454102. FINDINGS: Between May 15, 2014, and March 25, 2015, 78 patients were randomly assigned to receive nivolumab every 2 weeks plus ipilimumab every 12 weeks (n=38) or nivolumab every 2 weeks plus ipilimumab every 6 weeks (n=40). One patient in the ipilimumab every-6-weeks cohort was excluded before treatment; therefore 77 patients actually received treatment (38 in the ipilimumab every-12-weeks cohort; 39 in the ipilimumab every-6-weeks cohort). At data cut-off on Jan 7, 2016, 29 (76%) patients in the ipilimumab every-12-weeks cohort and 32 (82%) in the ipilimumab every-6-weeks cohort had discontinued treatment. Grade 3-4 treatment-related adverse events occurred in 14 (37%) patients in the ipilimumab every-12-weeks cohort and 13 (33%) patients in the every-6-weeks cohort; the most commonly reported grade 3 or 4 treatment-related adverse events were increased lipase (three [8%] and no patients), pneumonitis (two [5%] and one [3%] patients), adrenal insufficiency (one [3%] and two [5%] patients), and colitis (one [3%] and two [5%] patients). Treatment-related serious adverse events were reported in 12 (32%) patients in the ipilimumab every-12-weeks cohort and 11 (28%) patients in the every-6-weeks cohort. Treatment-related adverse events (any grade) prompted treatment discontinuation in four (11%) patients in the every-12-weeks cohort and five (13%) patients in the every-6-weeks cohort. No treatment-related deaths occurred. Confirmed objective responses were achieved in 18 (47% [95% CI 31-64]) patients in the ipilimumab every-12-weeks cohort and 15 (38% [95% CI 23-55]) patients in the ipilimumab every-6-weeks cohort; median duration of response was not reached in either cohort, with median follow-up times of 12·8 months (IQR 9·3-15·5) in the ipilimumab every-12-weeks cohort and 11·8 months (6·7-15·9) in the ipilimumab every-6-weeks cohort. In patients with PD-L1 of 1% or greater, confirmed objective responses were achieved in 12 (57%) of 21 patients in the ipilimumab every-12-weeks cohort and 13 (57%) of 23 patients in the ipilimumab every-6-weeks cohort. INTERPRETATION: In NSCLC, first-line nivolumab plus ipilimumab had a tolerable safety profile and showed encouraging clinical activity characterised by a high response rate and durable response. To our knowledge, the results of this study are the first suggestion of improved benefit compared with anti-PD-1 monotherapy in patients with NSCLC, supporting further assessment of this combination in a phase 3 study. FUNDING: Bristol-Myers Squibb.
引用
- Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016. PMID: 27932067. doi:10.1016/S1470-2045(16)30624-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。